Hearscape
← Therapeutics
Details checkedStrong evidenceCheckedcompany

GJB2-GT by Sensorion

Also known as: GJB2-GT, SENS-601

Sensorion

Primary source
Company
Sensorion
Program Type
Therapeutic
Modality
Gene Therapy
Stage
Preclinical
Status
Active
Target Gene
GJB2
Route / Mode
Intracochlear injection
Confidence
88%
Status Confidence
Status confirmed
Evidence Strength
Strong evidence
Last Reviewed
2026-05-31
Geography
France, Europe
Population
congenital, genetic, pre-lingual
Trial IDs
0
Mechanism

AAV-based gene therapy aims to restore connexin 26-related inner ear function in GJB2 hearing loss.

Indications
Hearing LossSensorineural Hearing LossGenetic Hearing Loss
Notes

Current public evidence supports an active preclinical/first-in-human preparation stage; Sensorion has publicly linked GJB2-GT to the code SENS-601.

Evidence & Sources
2 structured sources
company
Supports: canonicalName, aliases, company, allCompanies, targetGene, mechanism, indications
IDs: GJB2-GT
Open
company
Supports: aliases, stage, status, notes
IDs: SENS-601, GJB2-GT
Open
Key Events
2026-03-23
Sensorion stated GJB2-GT SENS-601 was advancing toward first-in-human development
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2